Trial Outcomes & Findings for Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme (NCT NCT00003474)

Last Updated: 2018-03-22

Results Overview

Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

40 participants

Primary outcome timeframe

12 months

Results posted on

2018-03-22

Participant Flow

Forty patients were recruited between March 1996 and April 2003. All study subjects were seen at the Burzynski Clinic in Houston TX

Participant milestones

Participant milestones
Measure	Antineoplaston Therapy Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Overall Study STARTED	40
Overall Study COMPLETED	26
Overall Study NOT COMPLETED	14

Reasons for withdrawal

Reasons for withdrawal
Measure	Antineoplaston Therapy Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Overall Study Not Evaluable	14

Baseline Characteristics

Antineoplaston Therapy in Treating Adults With Residual/Recurrent/Progressive Glioblastoma Multiforme

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Antineoplaston Therapy n=40 Participants Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Age, Continuous	48.8 Years n=5 Participants
Sex: Female, Male Female	24 Participants n=5 Participants
Sex: Female, Male Male	16 Participants n=5 Participants

PRIMARY outcome

Timeframe: 12 months

Outcome measures

Outcome measures
Measure	Antineoplaston Therapy n=26 Participants Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Number of Participants With Objective Response Complete Response	1 Participants
Number of Participants With Objective Response Partial Response	1 Participants
Number of Participants With Objective Response Stable Disease	5 Participants
Number of Participants With Objective Response Progressive Disease	19 Participants

SECONDARY outcome

Timeframe: 6 months, 12 months, 24 months, 36 months, 48 months, 60 months

Population: All study subjects receiving any Antineoplaston therapy

6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival

Outcome measures

Outcome measures
Measure	Antineoplaston Therapy n=40 Participants Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Percentage of Participants Who Survived 36 months overall survival	2.5 Percentage of participants
Percentage of Participants Who Survived 48 months overall survival	2.5 Percentage of participants
Percentage of Participants Who Survived 6 months overall survival	45.0 Percentage of participants
Percentage of Participants Who Survived 12 months overall survival	22.5 Percentage of participants
Percentage of Participants Who Survived 24 months overall survival	2.5 Percentage of participants
Percentage of Participants Who Survived 60 months overall survival	2.5 Percentage of participants

Adverse Events

Antineoplaston Therapy

Serious events: 17 serious events

Other events: 40 other events

Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure	Antineoplaston Therapy n=40 participants at risk Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Blood and lymphatic system disorders Hemoglobin	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Cardiac disorders Hypertension	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter Infection	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Dehydration	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Vomiting	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Bladder (urinary)	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Respiratory, thoracic and mediastinal disorders Infection (documented clinically): Lung (pneumonia)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Muscle weakness: Whole body/generalized	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Seizure	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Somnolence/depressed level of consciousness	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Syncope (fainting)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Pain: Head/headache	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Respiratory, thoracic and mediastinal disorders Dyspnea (shortness of breath)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Vascular disorders Thrombosis/thrombus/embolism	2.5% 1/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX

Other adverse events

Other adverse events
Measure	Antineoplaston Therapy n=40 participants at risk Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached. Antineoplaston therapy (Atengenal + Astugenal): Adults with a residual/recurrent/progressive Glioblastoma Multiforme will receive Antineoplaston therapy (Atengenal + Astugenal). The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Immune system disorders Allergic reaction/hypersensitivity (including drug fever)	17.5% 7/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Ear and labyrinth disorders Tinnitus	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Hemoglobin	17.5% 7/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Leukocytes (total WBC)	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Lymphopenia	20.0% 8/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Neutrophils/granulocytes (ANC/AGC)	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Blood and lymphatic system disorders Platelets	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Cardiac disorders Supraventricular and nodal arrhythmia: Sinus bradycardia	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Cardiac disorders Hypertension	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Cardiac disorders Hypotension	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Central Venous Catheter: Infection	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Non-functional	30.0% 12/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Other	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Central Venous Catheter: Thrombosis/embolism	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Constitutional Symptoms - Other	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Fatigue (asthenia, lethargy, malaise)	57.5% 23/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Insomnia	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Weight gain	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Fever	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
General disorders Edema	52.5% 21/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Endocrine disorders Cushingoid appearance	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Anorexia	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Constipation	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Diarrhea	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Dysphagia (difficulty swallowing)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Nausea	37.5% 15/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Gastrointestinal disorders Vomiting	27.5% 11/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Renal and urinary disorders Hemorrhage, GU: Urinary NOS	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Bladder (urinary)	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Blood	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Lung (pneumonia)	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Mucosa	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Sinus	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Upper airway NOS	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection (documented clinically): Urinary tract NOS	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection: Lung (pneumonia)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection: Mucosa	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Infections and infestations Infection: Opportunistic infection	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Albumin, serum-low (hypoalbuminemia)	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Alkaline phosphatase	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations GGT (gamma-Glutamyl transpeptidase)	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypercholesteremia	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hyperglycemia	30.0% 12/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypernatremia	62.5% 25/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypertriglyceridemia	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypocalcemia	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypoglycemia	17.5% 7/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypokalemia	85.0% 34/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hypomagnesemia	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Hyponatremia	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations Proteinuria	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations SGOT	15.0% 6/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Investigations SGPT	20.0% 8/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Ataxia (incoordination)	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Confusion	47.5% 19/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Dizziness	37.5% 15/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Memory impairment	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Mood alteration: Agitation	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Mood alteration: Anxiety	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Mood alteration: Depression	10.0% 4/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Neuropathy: motor	15.0% 6/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Psychosis (hallucinations/delusions)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Seizure	32.5% 13/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Somnolence/depressed level of consciousness	55.0% 22/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Speech impairment	12.5% 5/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Syncope (fainting)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Tremor	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Diplopia	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Ophthalmoplegia/diplopia (double vision)	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Vision-blurred vision	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Pain: Back	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Pain: Head/headache	37.5% 15/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Musculoskeletal and connective tissue disorders Pain: Joint	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Nervous system disorders Pain: Muscle	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Respiratory, thoracic and mediastinal disorders Cough	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Respiratory, thoracic and mediastinal disorders Dyspnea (shortness of breath)	22.5% 9/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Renal and urinary disorders Incontinence, urinary	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Renal and urinary disorders Urinary frequency/urgency	5.0% 2/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX
Vascular disorders Thrombosis/thrombus/embolism	7.5% 3/40 • 7 years, 3 months Forty patients were recruited between March 1996 and June 2003. All study subjects were seen at the Burzynski Clinic in Houston TX

Additional Information

S. R. Burzynski, MD, PhD

Burzynski Research Institute, Inc.

Phone: 713-335-5664

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place